gnkg168
Peptideexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2009 (NCT01035216)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Toll-like receptor 9AGONIST
TLR9 agonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- gnkg168
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01743807 | Phase 1 | Nov 1, 2012 | Northwestern University, University of British Columbia, University of Southern California |
| NCT01035216 | Phase 1 | Sep 1, 2009 | SBI Biotech Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Northwestern University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| SBI Biotech Co., Ltd. | For profit | 1 | 1 | 1 | 2009 |
| University of British Columbia | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Southern California | Academic/Hospital | 1 | 1 | 1 | 2012 |
4 organizations
Page 1 / 1